Market closedNon-fractional
Y-mAbs/YMAB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Y-mAbs
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
Ticker
YMAB
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
New York, United States
Employees
100
Website
www.ymabs.com
Y-mAbs Metrics
BasicAdvanced
$541M
Market cap
-
P/E ratio
-$0.50
EPS
0.65
Beta
-
Dividend rate
Price and volume
Market cap
$541M
Beta
0.65
Financial strength
Current ratio
6.15
Quick ratio
5.472
Long term debt to equity
0.295
Total debt to equity
1.191
Management effectiveness
Return on assets (TTM)
-9.87%
Return on equity (TTM)
-20.93%
Valuation
Price to revenue (TTM)
6.373
Price to book
5.44
Price to tangible book (TTM)
5.58
Price to free cash flow (TTM)
-30.622
Growth
Revenue change (TTM)
12.62%
Earnings per share change (TTM)
-70.73%
3-year revenue growth (CAGR)
47.87%
3-year earnings per share growth (CAGR)
-30.37%
What the Analysts think about Y-mAbs
Analyst Ratings
Majority rating from 7 analysts.
Y-mAbs Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$20M
-14.59%
Net income
-$6.6M
633.33%
Profit margin
-33.16%
759.07%
Y-mAbs Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.14
-$0.18
-$0.02
-$0.15
-
Expected
-$0.24
-$0.19
-$0.20
-$0.14
-$0.12
Surprise
-42.07%
-3.67%
-90.05%
10.46%
-
Y-mAbs News
AllArticlesVideos
Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Stock of Y-mAbs Therapeutics, Inc. - YMAB
GlobeNewsWire·5 days ago
Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer
GlobeNewsWire·4 weeks ago
Y-MABS SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Y-mAbs Therapeutics, Inc. (YMAB) on Behalf of the Company's Long-Term Shareholders and Encourages Investors to Contact the Firm
Accesswire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Y-mAbs stock?
Y-mAbs (YMAB) has a market cap of $541M as of July 27, 2024.
What is the P/E ratio for Y-mAbs stock?
The price to earnings (P/E) ratio for Y-mAbs (YMAB) stock is 0 as of July 27, 2024.
Does Y-mAbs stock pay dividends?
No, Y-mAbs (YMAB) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Y-mAbs dividend payment date?
Y-mAbs (YMAB) stock does not pay dividends to its shareholders.
What is the beta indicator for Y-mAbs?
Y-mAbs (YMAB) has a beta rating of 0.65. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Y-mAbs stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.